Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech

- LONDON, May 14, 2015 /PRNewswire/ -- Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful $275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. Bryan, Garnier & Co is the only European investment bank in the IPO syndicate. The Galapagos IPO on Nasdaq confirms the strong momentum of the European healthcare sector.      (Logo: http://photos.prnewswire.com/prnh/20150514/744149 ) Galapagos NV (Euronext: GLPG) announced today the pricing of its global offering totaling $275 million gross proceeds, initially filed for $150 million. The new shares were placed in a concurrent public offering in the US through ADSs at a price of $42.05 and private placement in Europe at a price of €37 per share. It is the largest Nasdaq IPO of a European biotech and one of three largest biotech IPO ever in Europe or in the US. Bryan, Garnier & Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.   Bryan Garnier & Co keeps on leading the financing of the European healthcare companies, in Europe and in the US:   For more information, please contact Anna Emelianenko (aemelianenko@bryangarnier.com | +33-1-56-68-75-00) or Daiana Hirte (dhirte@profilepr.fr | +33-1-56-26-72-00). About Galapagos: http://www.glpg.com About Bryan, Garnier & Co: http://www.bryangarnier.com